Survey Finds Patients with Rheumatoid Arthritis and Their Doctors Not Always on the Same Page

New York, NY—November 14, 2016

A large global survey finds gaps in communication between doctors who treat rheumatoid arthritis and their patients, even though most physicians believe good communication and patient engagement are important to achieve the best outcomes.

The research, "Understanding the Importance of a Patient’s Role in the Management of RA: Physician- and Patient-Based Survey" was presented at the American College of Rheumatology/Association of Rheumatology Health Professionals annual meeting on November 13 in Washington, DC.

"Rheumatoid Arthritis (RA) is a chronic, debilitating disease affecting 1.5 million people in the United States," said Allan Gibofsky, MD, a rheumatologist at Hospital for Special Surgery and senior study author. "The survey was launched to gain a better understanding of the similarities and differences in physician and patient perspectives, with the goal of improving patient care."

The RA NarRAtive Global Advisory Panel, a group of 39 rheumatology experts from around the world including Dr. Gibofsky, developed the surveys regarding RA treatment and management for both patients and health care providers. They were distributed in 15 countries between September  2014 and January 2016. More than 3900 patients and more than 1600 physicians completed the questionnaires.  

Some of the survey findings:

• Among the doctors, 90% of respondents were satisfied with their communications with patients, however, 68% acknowledged, ‘I wish my patients and I talked more about goals and treatment.’
• The majority of physicians believed that setting treatment goals and developing a disease management plan with their patients are essential for the successful management of RA. Yet, results from the patient survey revealed that few patients had shared their treatment goals with their doctor or realized they had a disease management plan in place.
• Only 53% of patients acknowledged that dialogue with their health care provider would optimize the management of their RA.
• 61% of patients felt uncomfortable voicing their concerns or fears to their doctor.
• RA remission was ranked higher in the physician survey than in the patient survey as a treatment goal. Patients were more likely to cite symptom reduction as a treatment goal.
• Overall, 88% of doctors agreed that patients who are involved in making treatment decisions tend to be more satisfied with their treatment experience; 74% felt that patients who are not involved are less likely to adhere to treatment.
• Doctors and patients had similar views on what they would most like to change about currently available RA medications, including the severity of side effects, cost and efficacy.

"Studies show that good communication and the involvement of the patient in decision-making are critical to achieve optimal care," said Dr. Gibofsky. "The hope is that this survey represents the beginning of a road map to address deficiencies so we can ultimately improve patient care."

#     #     #

Study Title: "Understanding the Importance of a Patient’s Role in the Management of RA: Physician- and Patient-Based Survey"

Authors: Ara Dikranian¹, James Galloway², Joern Kekow³, Cristiano A.F Zerbini⁴, Maria de la Vega⁵, Gavin Lee⁶, Anna Maniccia⁷, Eustratios Bananis⁸, Dario Ponce de Leon⁹ and Allan Gibofsky¹⁰, ¹San Diego Arthritis Medical Clinic, San Diego, CA, ²King's College, and King´s College Hospital, London, United Kingdom, ³University of Magdeburg, Clinic of Rheumatology, Magdeburg, Germany, ⁴Centro Paulista de Investigação Clinica, São Paulo, Brazil, 5CEIM Investigaciones Médicas, Buenos Aires, Argentina, ⁶Hong Kong Sanatorium & Hospital, Hong Kong SAR, China, ⁷Pfizer Inc, New York, NY, ⁸Pfizer Inc, Collegeville, PA, ⁹Pfizer Inc, Lima, Peru, ¹⁰Rheumatology, Weill Cornell Medicine, and Hospital for Special Surgery, New York, NY

Disclosures: A. Dikranian, Pfizer Inc, AbbVie, 5,Pfizer Inc, AbbVie, 8; J. Galloway, Pfizer Inc, 2,Pfizer Inc, MSD, AbbVie, Jannsen, 5; J. Kekow, None; C. A. F. Zerbini, Pfizer Inc, Merck, Sanofi, Amgen, Eli Lilly, Celltrion, Novartis, 2,Pfizer Inc, Eli Lilly, 8; M. de la Vega, Pfizer Inc, AbbVie, BMS, 5,Pfizer Inc, Amgen, Roche, 2; G. Lee, Eli Lilly, Pfizer Inc, 5; A. Maniccia, Pfizer Inc, 1,Pfizer Inc, 3; E. Bananis, Pfizer Inc, 3,Pfizer Inc, 1; D. Ponce de Leon, Pfizer Inc, 1,Pfizer Inc, 3; A. Gibofsky, Consultant-AbbVie, Amgen, Celgene, Medec, Pfizer, Antares, Iroko, Lilly, Novartis, Sandoz, UCB, Relburn, Samumed; Speaker-AbbVie, Celgene, Pfizer,  UCB. Shareholder-AbbVie, Amgen, BMS,  J&J, Pfizer, Regeneron.

The study was funded by Pfizer Inc.

About Hospital for Special Surgery
Hospital for Special Surgery (HSS) is the world’s leading academic medical center focused on musculoskeletal health. HSS is nationally ranked No. 1 in orthopedics and No. 3 in rheumatology by U.S. News & World Report (2017-2018), and is the first hospital in New York State to receive Magnet Recognition for Excellence in Nursing Service from the American Nurses Credentialing Center four consecutive times. HSS has one of the lowest infection rates in the country. HSS is an affiliate of Weill Cornell Medical College and as such all Hospital for Special Surgery medical staff are faculty of Weill Cornell. The hospital's research division is internationally recognized as a leader in the investigation of musculoskeletal and autoimmune diseases. HSS has locations in New York, New Jersey and Connecticut.
www.hss.edu